Pancreatic ductal adenocarcinoma remains one of the deadliest malignancies precisely because its dominant driver mutation — KRAS — has historically been undruggable. Now that KRASG12D inhibitors have finally entered clinical trials, a critical question has emerged almost immediately: how long before tumors evolve around them? Understanding that resistance mechanism could be the difference between a fleeting response and durable disease control.
Using RNA sequencing of cell lines engineered to resist MRTX1133, investigators identified a global epigenetic shift toward histone acetylation as the escape route tumors exploit. The acetyltransferase EP300 emerged as a central driver, and silencing it — either pharmacologically or genetically — restored sensitivity to MRTX1133. Downstream, the transcription factor FOSL1 was identified as the key prosurvival signal sustaining resistant cells; knockdown of FOSL1 alone recapitulated the re-sensitization effect. Because neither EP300 nor FOSL1 has a clinically mature inhibitor, the team pivoted to BET bromodomain inhibitors, which read acetylation marks genome-wide. Adding BET inhibitors to MRTX1133 re-sensitized multiple resistant cell lines and, critically, extended survival in murine PDAC models.
This work carries significant translational weight for several reasons. KRAS resistance mechanisms have been observed rapidly in lung cancer treated with KRASG12C inhibitors like sotorasib, suggesting a class-wide vulnerability. Epigenetic plasticity — rather than acquired point mutations — as a resistance scaffold is an important conceptual advance, implying that fixed genetic testing alone may miss the escape. BET inhibitors (including JQ1 and its clinical descendants) have a reasonably well-characterized safety profile, making combination trials feasible. The principal limitation here is the reliance on in vitro models and murine xenografts; patient tumor heterogeneity and stromal interactions in human PDAC are notoriously difficult to recapitulate. Still, the mechanistic clarity — EP300 → histone acetylation → FOSL1 → survival — provides a testable pathway for biomarker-driven clinical design. This study qualifies as meaningfully hypothesis-generating for the next wave of PDAC combination trials.